{"id":"losartan-chlorthalidone-in-fixed-dose","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Hyperuricemia"},{"rate":null,"effect":"Hypokalemia"},{"rate":null,"effect":"Cough"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Hyperglycemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Losartan is an angiotensin II receptor antagonist (ARB) that prevents vasoconstriction and aldosterone release, reducing blood pressure through vasodilation and decreased peripheral resistance. Chlorthalidone is a long-acting thiazide-like diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, promoting urinary excretion of water and electrolytes. The fixed-dose combination provides complementary antihypertensive effects through different mechanisms.","oneSentence":"Losartan blocks angiotensin II receptors to lower blood pressure, while chlorthalidone is a thiazide-like diuretic that reduces fluid volume and sodium reabsorption.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:19:27.159Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension (essential hypertension management)"}]},"trialDetails":[{"nctId":"NCT04927299","phase":"PHASE3","title":"Efficacy and Safety of Losartan/Chlorthalidone vs Losartan/Hydrochlorothiazide in Essential Arterial Hypertension","status":"COMPLETED","sponsor":"Laboratorios Silanes S.A. de C.V.","startDate":"2022-06-30","conditions":"Essential Arterial Hypertension","enrollment":163},{"nctId":"NCT05090449","phase":"PHASE1","title":"Non-interaction Study of Chlorthalidone and Losartan in Fixed Combination, in Healthy Subjects, Under Fasting Conditions","status":"COMPLETED","sponsor":"Laboratorios Silanes S.A. de C.V.","startDate":"2019-05-01","conditions":"Healthy","enrollment":36},{"nctId":"NCT02521246","phase":"PHASE3","title":"Efficacy and Safety of Candesartan Associated With Chlorthalidone Versus Losartan Associated With Hydrochlorothiazide (Hyzaar®) in Essential Hypertension Control","status":"WITHDRAWN","sponsor":"EMS","startDate":"2016-11","conditions":"Essential Arterial Hypertension","enrollment":""},{"nctId":"NCT02521233","phase":"PHASE3","title":"Efficacy and Safety of Candesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control","status":"WITHDRAWN","sponsor":"EMS","startDate":"2016-11","conditions":"Essential Arterial Hypertension","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["LOS/CHLORTHA"],"phase":"phase_3","status":"active","brandName":"Losartan/Chlorthalidone in fixed dose","genericName":"Losartan/Chlorthalidone in fixed dose","companyName":"Laboratorios Silanes S.A. de C.V.","companyId":"laboratorios-silanes-s-a-de-c-v","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Losartan blocks angiotensin II receptors to lower blood pressure, while chlorthalidone is a thiazide-like diuretic that reduces fluid volume and sodium reabsorption. Used for Hypertension (essential hypertension management).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}